Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) shares, rose in value on Friday, June 11, with the stock price up by 1.20% to the previous day’s close as strong demand from buyers drove the stock to $1.16.
Actively observing the price movement in the recent trading, the stock is buoying the session at $1.15, falling within a range of $1.13 and $1.17. Referring to stock’s 52-week performance, its high was $3.50, and the low was $0.63. On the whole, SLRX has fluctuated by -4.17% over the past month.
As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.06, which is expected to increase to -$0.04 for fiscal year -$0.23 and then to about -$0.28 by fiscal year 2022. Data indicates that the EPS growth is expected to be 54.00% in 2022, while the next year’s EPS growth is forecast to be -21.70%.
Analysts have estimated the company’s revenue for the quarter at $1.28 million, with a low estimate of $1.1 million and a high estimate of $1.44 million. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $5.67 million, representing an increase of 8.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that SLRX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Sell.
2 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 2 recommend it as a Buy and 0 called the SLRX stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of SLRX currently trading nearly -8.76% and -8.88% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.13, while the 7-day volatility ratio is showing 9.93% which for the 30-day chart, stands at 9.89%. Furthermore, Salarius Pharmaceuticals Inc. (SLRX)’s beta value is 1.57, and its average true range (ATR) is 0.12. The company’s stock has been forecasted to trade at an average price of $4.40 over the course of the next 52 weeks, with a low of $3.80 and a high of $5.00. Based on these price targets, the low is -227.59% off current price, whereas the price has to move -331.03% to reach the yearly target high. Additionally, analysts’ median price of $4.40 is likely to be welcomed by investors because it represents a decrease of -279.31% from the current levels.
Data on historical trading for Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) indicates that the trading volumes over the past 10 days have averaged 6.57 million and over the past 3 months, they’ve averaged 1.61 million. According to company’s latest data on outstanding shares, there are 44.73 million shares outstanding.
Nearly 0.30% of Salarius Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 38.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.63 million shares as on May 27, 2021, resulting in a short ratio of 1.66. According to the data, the short interest in Salarius Pharmaceuticals Inc. (SLRX) stood at 3.64% of shares outstanding as of May 27, 2021; the number of short shares registered in Apr 29, 2021 reached 1.29 million. The stock has risen by 26.37% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLRX stock heading into the next quarter.